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OBJECTIVE—Diabetic dyslipoproteinemia is characterized by
low HDL cholesterol and high triglycerides. We examined the
association of lipoprotein particle size and concentration mea-
sured by nuclear magnetic resonance (NMR) spectroscopy with
clinical type 2 diabetes.
RESEARCH DESIGN AND METHODS—This was a prospec-
tive study of 26,836 initially healthy women followed for 13 years
for incident type 2 diabetes (n  1,687). Baseline lipids were
measured directly and lipoprotein size and concentration by
NMR. Cox regression models included nonlipid risk factors (age,
race, smoking, exercise, education, menopause, blood pressure,
BMI, family history, A1C, and C-reactive protein). NMR lipopro-
teins were also examined after further adjusting for standard
lipids.
RESULTS—Incident diabetes was signiﬁcantly associated with
baseline HDL cholesterol, triglycerides, and NMR-measured size
and concentration of LDL, IDL, HDL, and VLDL particles. The
associations of these particles differed substantially by size.
Small LDLNMR and small HDLNMR were positively associated
with diabetes (quintile 5 vs. 1 [adjusted hazard ratios and 95%
CIs], 4.04 [3.21–5.09] and 1.84 [1.54–2.19], respectively). By
contrast, large LDLNMR and large HDLNMR were inversely asso-
ciated (quintile 1 vs. 5, 2.50 [2.12–2.95] and 4.51 [3.68–5.52],
respectively). For VLDLNMR, large particles imparted higher risk
than small particles (quintile 5 vs. 1, 3.11 [2.35–4.11] and 1.31
[1.10–1.55], respectively). Lipoprotein particle size remained
signiﬁcant after adjusting for standard lipids and nonlipid
factors.
CONCLUSIONS—In this prospective study of women, NMR
lipoprotein size and concentrations were associated with inci-
dent type 2 diabetes and remained signiﬁcant after adjustment
for established risk factors, including HDL cholesterol and
triglycerides. Diabetes 59:1153–1160, 2010
T
he dyslipoproteinemia of insulin resistance and
type 2 diabetes is characterized by low HDL
cholesterol and high triglycerides, despite nor-
mal or near-normal LDL cholesterol levels (1).
Under normal physiologic conditions, insulin results in
decreased hepatic synthesis and secretion of VLDL parti-
cles. However, when hepatic insulin signaling is impaired
in insulin-resistant patients, triglyceride-rich VLDL pro-
duction and secretion are increased (2). This increase in
VLDL is typically associated with reduction in HDL cho-
lesterol levels, in part related to the transfer of cholesteryl
ester from the triglyceride-rich lipoproteins to HDLs. In
addition, when these triglyceride-rich VLDL particles are
subjected to further lipolysis, they give rise to small,
cholesterol-poor LDL particles and hence the association
with low or nonelevated LDL cholesterol levels. It has
been proposed that an abundance of these small dense
LDL particles should be considered part of this dyslipopro-
teinemia. However, small LDL particles cluster metaboli-
cally with other risk factors, particularly high triglycerides
and low HDL cholesterol (3), and it is unclear if small LDL
contribute independent information for prediction of type
2 diabetes (4). Even less is known about the predictive
value of particle size or subclass concentrations for HDLs
or VLDLs.
One method to measure lipoprotein particle size and
concentration is nuclear magnetic resonance (NMR) spec-
troscopy. This technique simultaneously quantiﬁes the size
and concentration (“number”) of lipoprotein particles ex-
pressed each as an average particle size (in nanometers)
or as lipoprotein particle concentration (in particle mol/l)
(5–8). By contrast, standard lipid tests quantify the cho-
lesterol or triglyceride content of lipoproteins, without
providing size-speciﬁc lipoprotein particle information.
NMR lipoproteins have been examined in individuals with
insulin resistance or type 2 diabetes, with small LDLs,
small HDLs, and large VLDLs associated positively and
large HDLs associated inversely, with insulin resistance
measured by the euglycemic clamp technique (9) or the
frequently sampled intravenous glucose tolerance test
(9,10).
Given this pathophysiological relationship between in-
sulin resistance and lipoproteins, we hypothesized that
NMR-measured lipoproteins would predict incident type 2
diabetes in a primary prevention setting. Therefore, we
conducted this prospective study of initially healthy
women to determine 1) whether NMR-measured lipopro-
tein particle size and concentrations are associated with
incident type 2 diabetes, 2) how they compare with
chemically measured HDL cholesterol and triglycerides,
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established risk factors for diabetes.
RESEARCH DESIGN AND METHODS
Study participants were drawn from the Women’s Health Study (WHS), a
completed randomized, double-blinded, placebo-controlled trial of low-dose
aspirin and vitamin E in the primary prevention of cardiovascular disease
(CVD) and cancer in women (11–13). WHS participants were apparently
healthy female health care professionals, aged 45 years, who were free of
self-reported CVD and cancer at study entry (1992–1995). At the time of
enrollment, women gave written informed consent and completed question-
naires on demographics, anthropometrics, medical history, and lifestyle
factors. They were also asked to provide a baseline blood sample; 28,345
women did so, and of these, 98.5% (n  27,909) had NMR measurements. For
this study, we excluded women missing other lipids (n  33), those with
self-reported baseline type 2 diabetes (n  770), and those with baseline A1C
6.5% (n  270), leaving 26,836 women for analysis. We also repeated the
analyses after excluding 169 women with A1C 6.0 and 6.5%. The study was
approved by the institutional review board of the Brigham and Women’s
Hospital (Boston, MA).
Laboratory measurements. EDTA blood samples were obtained at the time
of enrollment into the WHS and stored in vapor-phase liquid nitrogen
(170°C). In a laboratory certiﬁed by the National Heart, Lung, and Blood
Institute/Centers for Disease Control and Prevention Lipid Standardization
Program, baseline samples were thawed and analyzed for standard lipids.
Direct determination of concentrations of total cholesterol, HDL cholesterol,
LDL cholesterol, and triglycerides was simultaneously performed on the
Hitachi 917 analyzer using reagents and calibrators from Roche Diagnostics
(Indianapolis, IN). Total cholesterol was assayed enzymatically. LDL choles-
terol was determined by a homogenous direct method from Roche Diagnos-
tics. HDL cholesterol was determined using a direct enzymatic colorimetric
assay. Triglycerides were measured enzymatically with correction for endog-
enous glycerol. Coefﬁcients of variation (CVs) for these lipids were 3%.
Samples for lipoprotein particle analysis by proton NMR spectroscopy
were thawed, aliquoted (200 l), refrozen, and shipped on dry ice to
LipoScience (Raleigh, NC). Particle concentrations of lipoproteins of different
sizes were calculated from the measured amplitudes of their spectroscopically
distinct lipid methyl group NMR signals (7,14). Weighted-average lipoprotein
particle sizes are derived from the sum of the diameter of each subclass
multiplied by its relative mass percentage based on the amplitude of its methyl
NMR signal. The NMR lipoprotein variables that we examined are those that
are provided when ordering an NMR lipoprotein proﬁle for clinical use (7).
CVs ranged from 0.4 to 7.1%, except for IDLNMR (13.1%) and medium HDLNMR
particle concentration (30%). A1C was measured with turbidimetric immu-
noinhibition using packed erythrocytes (Roche Diagnostics). High-sensitive
C-reactive protein (hsCRP) was measured using a high-sensitivity immunotur-
bidimetric assay on the Hitachi 917 analyzer (Roche Diagnostics), using
reagents and calibrators from Denka Seiken.
Ascertainment of type 2 diabetes. Incident clinical type 2 diabetes in WHS
participants was ascertained by self-report on annual follow-up questionnaires
through March 2008 as previously described (15,16). Conﬁrmation of diabetes
was conducted using American Diabetes Association diagnostic criteria (17).
Self-reported cases were then further investigated either by telephone inter-
view with a physician or by a previously validated self-administered supple-
mental questionnaire that inquired about symptoms, diagnostic diabetes
testing, and use of diabetes medications. The response rate was high, with
90% response rate to either telephone interview or supplemental question-
naire by women who self-reported diabetes. Glucose screening rates in this
population were similar to contemporaneous screening rates in the general
population (18), with 68.2% of nondiabetic women having reported a screening
fasting glucose performed in the prior 3 years.
Statistical analysis. Statistical analyses were performed using STATA
version 10.1 (STATA, College Station, TX). Statistical comparisons were
obtained from Student t tests for continuous variables expressed as means,
from Wilcoxon rank-sum tests for variables expressed as medians, and 
2 tests
for categorical variables.
Following guidelines from the Department of Health and Human Services
(19), lipids and lipoproteins were divided into quintiles based on the distribu-
tion among women not taking hormone replacement. Cox proportional hazard
regression models were used to calculate the hazard ratios (HRs) and 95% CIs
according to these quintiles. The proportional hazard assumption was tested
using Schoenfeld residuals and the natural logarithm of follow-up time. Some
of the variables did not satisfy the proportionality assumption; hence, we also
divided the follow-up time into the ﬁrst and second 6 years, ﬁnding no
substantial differences within each 6-year period. Stronger associations were
noted for NMR lipoproteins with diabetes during the ﬁrst 6 years compared
with the second 6 years of follow-up, but the relative magnitude of associa-
tions was generally similar within each 6-year period; therefore, we report the
main results for the overall follow-up period unless otherwise speciﬁed.
We initially considered two levels of adjustment for 1) age, race, and
randomized treatment assignment (minimally adjusted; model 1); and 2)
covariates in model 1 plus smoking status, exercise, education, menopausal
status, hormone use, blood pressure, BMI, family history of diabetes, A1C, and
hsCRP (nonlipid risk factors; model 2). To determine the magnitude of
association of NMR lipoproteins with diabetes independent of standard lipids,
we additionally adjusted model 2 for triglycerides and HDL and LDL choles-
terol and evaluated the association of NMR lipoproteins with diabetes using
likelihood ratio 
2 tests. Since lipoprotein particles are metabolically interre-
lated (7,20), NMR lipoproteins were also analyzed in a single model that
included the nine NMR lipoprotein subclasses (two LDLNMR, one IDLNMR,
three HDLNMR, and three VLDLNMR lipoprotein subclasses) in addition to the
nonlipid risk factors, in order to estimate the independent associations of
these correlated lipoproteins with diabetes.
Based on prior work from this cohort suggesting that nonfasting concen-
trations of certain lipids may be superior to fasting concentrations for risk
prediction (21,22), we examined whether fasting status modiﬁed the associa-
tion of NMR lipoproteins with diabetes. Statistical tests for interaction
between fasting status and lipoproteins in relation to diabetes were obtained
using likelihood ratio tests.
We repeated the analyses after excluding 169 women with A1C 6.0 and
6.5%, with similar results. P value for linear trend was obtained using the
quantile number as a predictor. All P values were two tailed.
RESULTS
During a median follow-up of 13.3 years (interquartile
range 12.3–13.8), a total of 1,687 incident cases of clinical
type 2 diabetes occurred. Table 1 shows the baseline
characteristics of participants according to the develop-
ment of diabetes during follow-up. In comparison with the
small differences noted in LDL cholesterol between case
subjects and noncase subjects, the NMR-measured con-
centration of total LDLNMR particles was much higher in
case subjects. This resulted from case subjects having
more small LDLNMR particles and IDLNMR particles but
fewer large LDLNMR particles. Case subjects also had
signiﬁcantly less HDLNMR particles (total) due to having
fewer large HDLNMR particles, despite having more small
HDLNMR particles. VLDLNMR particles were higher in case
subjects (both large and small). In accordance with these
results, average particle size in case versus control sub-
jects was smaller for LDLNMR and HDLNMR, and larger for
VLDLNMR.
LDL measures. HRs for diabetes according to quintiles of
LDL cholesterol and LDLNMRparticle concentration and
size are shown in Table 2. In fully adjusted models, neither
total cholesterol (data not shown) nor LDL cholesterol
was associated with diabetes (P for trend 0.53 and 0.64,
respectively), but other LDL measures, such as LDLNMR
particle concentration and size, were signiﬁcantly associ-
ated with diabetes (P for trend 0.001).
LDLNMR particles differed substantially in their associa-
tion with diabetes according to their size. Large LDLNMR
particles were inversely associated (adjusted HR 2.50 [95%
CI 2.12–2.95]) for quintile 1 vs. 5, while small LDLNMR
particles were positively associated with diabetes (4.04
[3.21–5.09]) for quintile 5 vs. 1. The concentration of
IDLNMR particles, a subclass of LDL particles whose den-
sity and size are intermediate between small VLDL and
large LDL, was positively associated with diabetes, similar
in association to small VLDLNMR (shown in Table 4) but
different from the inverse association of large LDLNMR.
Total LDLNMR particle concentration (IDLNMR  large
LDLNMR  small LDLNMR) was positively associated with
diabetes, and the smaller the average LDLNMR particle size
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mally adjusted model 1 were generally stronger than
model 2, which had further adjustment for other factors.
HDL measures. HDL cholesterol was inversely associated
with diabetes (Table 3), with quintile 1 vs. 5 associated
with fourfold increased risk. While total HDLNMR particle
concentration was also inversely associated with diabetes
(quintile 1 vs. 5, adjusted HR 1.20 [95% CI 1.03–1.40]), it
was only large HDLNMR particles that were inversely
associated, with quintile 1 (4 mol/l) imparting 4.5-fold
increased risk of diabetes compared with quintile 5. Inter-
estingly, this inverse association noted for large HDLNMR
particles was not noted for smaller HDLNMR particles.
Instead, there was nearly twofold increased risk associ-
ated with the highest concentration of small HDLNMR
particles. This was also reﬂected in HDLNMR average
particle size, with smaller HDLNMR size having 4.5-fold
higher risk of diabetes.
VLDL measures. Higher concentrations of triglycerides
and triglyceride-rich VLDL particles were associated with
higher risk of diabetes (Table 4). Large VLDLNMR particles,
which carry more triglycerides than smaller particles and
correlate more with insulin resistance (9), had the stron-
gest association of the VLDL particles with diabetes, with
more than threefold increased risk for quintile 5 vs. 1.
Small VLDLNMR also showed positive association with
diabetes but less than large particles. Thus, larger average
VLDLNMR size correlated with higher risk of diabetes,
although not to the same extent as smaller LDLNMR or
HDLNMR size, both of which had higher absolute and
relative risk.
Figure 1 summarizes the adjusted HRs and 95% CIs for
incident diabetes associated with extreme quintiles of the
NMR lipoproteins, standard lipids, and A1C, ranked ac-
cording to the magnitude of the HRs.
Other analyses. When we repeated the analyses using
continuous variables instead of quintiles, similar results
were obtained. Similar results were also found after addi-
tionally excluding 169 women with A1C 6.0%. A similar
pattern of ﬁndings was noted when analyses were strati-
ﬁed by median follow-up time into the ﬁrst and second 6
years. Overall, stronger associations were noted for A1C
and NMR lipoproteins with diabetes during the ﬁrst 6 years
compared with the second 6 years of follow-up, but the
relative magnitude of associations was generally similar
and signiﬁcant both early and late in follow-up. For
example, the adjusted HRs (95% CIs) for extreme quintile
values of LDLNMR, HDLNMR, and VLDLNMR size were 6.56
TABLE 1
Baseline characteristics of participants according to incident type 2 diabetes
No diabetes Diabetes P*
n 25,149 1,687
Age (years) 54.6  7.10 54.6  6.55 0.96
Current smoking (%) 11.5 13.2 0.04
Hypertension (%) 22.4 47.0 0.001
Postmenopausal status (%) 54.0 55.6 0.001
Postmenopausal hormone use (%) 44.3 40.4 0.002
Fasting (%) 75.8 78.6 0.01
BMI (kg/m
2) 25.4  4.6 30.6  5.9 0.001
A1C (%) 4.98 (4.83–5.15) 5.28 (5.07–5.53) 0.001
Family history of diabetes (%) 23.4 43.9 0.001
hsCRP (mg/l) 1.84 (0.74–3.98) 4.42 (2.26–7.34) 0.001
Lipid concentrations (mg/dl)
Total cholesterol 208 (184–235) 213 (187–242) 0.001
LDL cholesterol 121 (100–144) 126 (104–152) 0.001
HDL cholesterol 53 (44–63) 42 (36–50) 0.001
Triglycerides 115 (82–167) 175 (126–247) 0.001
NMR lipoprotein particle concentrations
LDLNMR (nmol/l)
Total 1,260 (1,024–1,570) 1,587 (1,288–1,944) 0.001
Large 551 (414–692) 424 (268–589) 0.001
Small 632 (382–972) 1,075 (714–1,502) 0.001
IDLNMR 32 (10–66) 51 (22–93) 0.001
HDLNMR (mol/l)
Total 35.1 (31.2–39.5) 34.2 (30.1–39.0) 0.001
Large 7.8 (5.3–10.5) 4.6 (3.0–6.8) 0.001
Medium 2.7 (0.8–6.0) 2.7 (0.8–5.8) 0.68
Small 23.6 (19.9–27.2) 25.5 (22.0–28.8) 0.001
VLDLNMR (nmol/l)
Total 68.0 (48.9–90.1) 73.8 (55.1–94.6) 0.001
Large 1.3 (0.3–3.6) 3.0 (1.4–5.5) 0.001
Medium 20.8 (11.1–31.8) 20.9 (11.9–32.6) 0.13
Small 44.5 (32.2–57.8) 48.2 (36.7–59.9) 0.001
NMR average particle size (nm)
LDLNMR size 21.4 (20.9–21.9) 20.7 (20.1–21.3) 0.001
HDLNMR size 9.0 (8.7–9.4) 8.6 (8.4–8.9) 0.001
VLDLNMR size 46.3 (42.0–51.6) 51.1 (46.6–56.7) 0.001
Data are median (interquartile range) or means  SD, unless otherwise indicated. *P values were obtained from Student t test for continuous
variables expressed as means, from Wilcoxon rank-sum tests for variables expressed as medians, and 
2 tests for categorical variables.
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spectively, early in follow-up; and 3.74 (2.88–4.85), 4.12
(3.07–5.53), and 2.90 (2.26–3.73), respectively, late in
follow-up.
We also examined the effect of fasting status (Fig. 2),
noting generally similar results for fasting and nonfasting
lipoprotein measurements (all P for interaction with fast-
ing status 0.05). However, there were several borderline
signiﬁcant interactions noted for fasting status with each
of small LDLNMR particles, LDLNMR size, and HDLNMR size
in relation to diabetes (P for interaction 0.08, 0.06, and
0.05, respectively). Moreover, while the P value for inter-
action was nonsigniﬁcant, nonfasting large VLDLNMR par-
ticles carried much higher risk for diabetes than fasting
measurements.
When we evaluated all nine NMR-measured lipoprotein
particle concentrations in one model that also adjusted for
nonlipid risk factors, we found that large and small
LDLNMR, large and small HDLNMR, and large VLDLNMR
remained associated with diabetes. IDLNMR and small
VLDLNMR particles were no longer signiﬁcant (P  0.38
and 0.62, respectively). Medium HDLNMR and medium
VLDLNMR particles now showed inverse associations with
diabetes.
TABLE 2
Association of LDL measures with incident type 2 diabetes
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
P for
trend
LDL cholesterol (mg/dl) 97.3 97.4–115.2 115.3–131.9 132.0–153.7 153.7
Model 1 Referent 0.99 (0.85–1.16) 1.14 (0.98–1.33) 1.10 (0.94–1.29) 1.57 (1.35–1.82) 0.001
Model 2 Referent 0.94 (0.80–1.11) 0.94 (0.80–1.10) 0.85 (0.72–1.00) 1.08 (0.93–1.26) 0.64
LDLNMR particle concentrations
Total LDLNMR (nmol/l) 957 958–1,155 1,156–1,373 1,374–1,680 1,680
Model 1 Referent 1.31 (1.02–1.68) 2.29 (1.83–2.87) 3.78 (3.05–4.67) 6.49 (5.29–7.96) 0.001
Model 2 Referent 1.07 (0.83–1.38) 1.48 (1.18–1.87) 1.83 (1.47–2.28) 2.53 (2.04–3.13) 0.001
Large LDLNMR (nmol/l) 361 362–476 477–577 578–698 698
Model 1 4.25 (3.64–4.97) 1.90 (1.59–2.26) 1.55 (1.29–1.86) 1.27 (1.05–1.53) Referent 0.001
Model 2 2.50 (2.12–2.95) 1.44 (1.20–1.73) 1.37 (1.14–1.66) 1.27 (1.04–1.54) Referent 0.001
Small LDLNMR (nmol/l) 346 347–553 554–774 775–1,134 1,134
Model 1 Referent 1.85 (1.42–2.40) 3.00 (2.35–3.83) 5.20 (4.13–6.55) 10.19 (8.17–12.72) 0.001
Model 2 Referent 1.54 (1.18–2.02) 2.09 (1.63–2.68) 2.62 (2.06–3.32) 4.04 (3.21–5.09) 0.001
IDLNMR (nmol/l) 5 6–20 21–39 40–72 72
Model 1 Referent 1.27 (1.04–1.56) 1.75 (1.45–2.12) 2.22 (1.85–2.66) 3.07 (2.58–3.65) 0.001
Model 2 Referent 1.16 (0.94–1.42) 1.35 (1.11–1.65) 1.40 (1.16–1.68) 1.66 (1.39–1.99) 0.001
LDLNMR average size (nm) 20.5 20.6–21.0 21.1–21.5 21.6–21.9 21.9
Model 1 9.99 (8.03–12.44) 5.54 (4.41–6.96) 3.07 (2.44–3.88) 1.83 (1.41–2.38) Referent 0.001
Model 2 4.16 (3.30–5.24) 3.04 (2.40–3.86) 2.21 (1.74–2.81) 1.63 (1.25–2.13) Referent 0.001
Data are HR (95% CI) and (ranges minimum–maximum) and are given for each quintile. P for trend obtained from using median quantile as
a dependent variable in Cox regression models. Model 1: adjusted for age, race, and randomized treatment assignment. Model 2: adjusted for
model 1 variables plus smoking, exercise, education, menopausal status, hormone use, blood pressure, BMI, family history of diabetes, A1C,
and hsCRP.
TABLE 3
Association of HDL measures with incident type 2 diabetes
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
P for
trend
HDL cholesterol (mg/dl) 39.8 39.9–46.3 46.4–52.8 52.9–61.8 61.8
Model 1 9.52 (7.89–11.48) 5.32 (4.37–6.48) 2.94 (2.38–3.63) 1.84 (1.47–2.30) Referent 0.001
Model 2 4.01 (3.28–4.92) 3.14 (2.56–3.86) 2.05 (1.65–2.55) 1.54 (1.23–1.93) Referent 0.001
HDLNMR particle concentrations
Total HDLNMR (mol/l) 29.0 29.1–31.9 32.0–34.3 34.4–37.3 37.3
Model 1 1.60 (1.39–1.83) 1.21 (1.04–1.40) 1.07 (0.92–1.24) 1.01 (0.88–1.17) Referent 0.001
Model 2 1.20 (1.03–1.40) 1.07 (0.91–1.25) 0.91 (0.77–1.07) 0.88 (0.75–1.02) Referent 0.008
Large HDLNMR (mol/l) 4 4.1–5.8 5.9–7.7 7.8–10.0 10.0
Model 1 9.89 (8.20–11.93) 5.36 (4.39–6.55) 3.31 (2.69–4.08) 1.84 (1.47–2.31) Referent 0.001
Model 2 4.51 (3.68–5.52) 3.19 (2.58–3.94) 2.54 (2.04–3.15) 1.72 (1.36–2.17) Referent 0.001
Medium HDLNMR (mol/l) 0.2 0.3–1.4 1.5–3.0 3.1–5.6 5.6
Model 1 Referent 1.19 (1.01–1.41) 1.23 (1.04–1.46) 1.20 (1.01–1.41) 1.11 (0.95–1.30) 0.47
Model 2 Referent 1.14 (0.96–1.35) 1.01 (0.84–1.20) 1.04 (0.87–1.23) 1.03 (0.87–1.21) 0.72
Small HDLNMR (mol/l) 18.8 18.9–21.9 22.0–24.4 24.5–27.3 27.3
Model 1 Referent 1.46 (1.20–1.77) 1.69 (1.40–2.04) 2.21 (1.85–2.65) 2.68 (2.25–3.18) 0.001
Model 2 Referent 1.19 (0.97–1.45) 1.36 (1.12–1.65) 1.51 (1.25–1.81) 1.84 (1.54–2.19) 0.001
HDLNMR average size (nm) 8.5 8.6–8.7 8.8–9.0 9.1–9.4 9.4
Model 1 12.01 (9.31–15.50) 9.04 (6.95–11.75) 4.78 (3.67–6.23) 2.10 (1.59–2.79) Referent 0.001
Model 2 4.56 (3.50–5.93) 3.97 (3.03–5.21) 3.08 (2.35–4.03) 1.72 (1.29–2.29) Referent 0.001
Data are adjusted HR (95% CI) and (ranges minimum–maximum) and are given for each quintile. See Table 2 legend for model adjustments.
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lipoproteins are correlated with standard lipids, in partic-
ular HDL cholesterol and triglycerides, we performed Cox
models that adjusted for triglycerides and HDL and LDL
cholesterol in addition to the nonlipid (model 2) risk
factors. Although the associations were attenuated,
smaller particle size for LDLNMR and HDLNMR remained
signiﬁcant (quintile 1 vs. 5, HR 1.79, [95% CI 1.37–2.33] and
2.39 [1.75–3.28], respectively; P for trend 0.001 for both),
as did larger VLDLNMR particle size (quintile 5 vs. 1, 2.04
[1.63–2.56]; P for trend 0.001). The change in the likeli-
hood ratio 
2 tests was signiﬁcant for adding either
LDLNMR, HDLNMR, or VLDLNMR particle size to models that
already included standard lipids and nonlipid risk factors
(change in 
2 24.53, 48.56, and 59.51, respectively; P 
0.0001 for all three).
Finally, we identiﬁed 8,101 women (number of incident
diabetes cases  132) who had normal values of both
triglycerides and HDL cholesterol using median values as
cut points (triglycerides 117 mg/dl and HDL cholesterol
52 mg/dl). Compared with the rest of the cohort, these
women were more likely to be hypertensive and hormone
users. We then examined the association of small LDLNMR
with incident diabetes in these women after adjusting for
nonlipid risk factors (including hypertension and hormone
use). Higher concentration of small LDLNMR particles was
signiﬁcantly associated (P for trend 0.003) with incident
diabetes, despite that these women had normal levels of
triglycerides and HDL cholesterol (fully adjusted HR for
the top versus bottom quintile of small LDLNMR 3.95 [95%
CI 1.63–9.55]).
DISCUSSION
Consistent with prior studies in individuals with insulin
resistance, we found that in initially healthy women followed
prospectively for incident clinical type 2 diabetes, both
triglycerides and HDL cholesterol were independently asso-
ciated with diabetes but not LDL or total cholesterol. Fur-
thermore, NMR-measured size and concentrations of LDL,
HDL, and VLDL particles were also associated with diabetes,
independent of triglycerides, HDL cholesterol, and other
factors. The associations of lipoprotein particles differed
markedly by size. Smaller average size of LDLNMR and
HDLNMR particles, as well as the concentration of small
LDLNMR and HDLNMR particles, was associated with in-
creased risk, while the concentration of large LDLNMR and
HDLNMR particles carried lower risk. Large VLDLNMR parti-
cles carried higher risk than small particles. LDLNMR,
HDLNMR, and VLDLNMR particle size remained associated
with diabetes in models that already included standard lipids
and nonlipid risk factors, adding incremental risk informa-
tion beyond that obtained from established risk factors.
A uniting feature of these lipoprotein alterations and
their association with type 2 diabetes may be a state of
insulin resistance. The associations we found in this study
in relation to the NMR-measured lipoproteins have been
previously linked to insulin resistance as measured by the
euglycemic clamp (9). Garvey et al. (9) demonstrated a
progressive increase in insulin resistance associated with
larger VLDLNMR size, smaller LDLNMR size, and smaller
HDLNMR size, all of which are consistent with our ﬁndings
in relation to predicting incident type 2 diabetes. In 830
subjects with insulin resistance followed in the Insulin
Resistance Atherosclerosis Study over a 5-year period,
NMR-measured larger VLDLNMR size and smaller HDLNMR
particles were independently associated with increased
risk of type 2 diabetes (14), while LDLNMR size and LDLNMR
particles were not signiﬁcant independent of other risk
factors. Factor analysis revealed a single factor that cor-
related with insulin resistance accounted for nearly half
the variance in these lipoprotein measures (10).
Our study, which was conducted in a large population of
healthy women, found independent associations for inci-
dent diabetes with baseline LDLNMR size and concentra-
tion, with larger LDLNMR particles associated with lower
risk and smaller LDLNMR particles associated with higher
risk. Moreover, small LDLNMR imparted higher risk of
diabetes even in women with normal triglyceride and
HDL cholesterol levels. The inverse association of large
LDLNMR particles with type 2 diabetes contrasts with the
TABLE 4
Association of VLDL measures with incident type 2 diabetes
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
P for
trend
Triglycerides (mg/dl) 70 71–95 96–125 126–178 178
Model 1 Referent 1.73 (1.30–2.31) 2.47 (1.88–3.25) 4.91 (3.81–6.33) 8.88 (6.94–11.37) 0.001
Model 2 Referent 1.36 (1.01–1.83) 1.57 (1.18–2.08) 2.57 (1.98–3.35) 3.71 (2.87–4.80) 0.001
VLDLNMR particle concentrations
Total VLDLNMR (nmol/l) 45.6 45.7–61.8 61.9–77.2 77.3–96.8 96.8
Model 1 Referent 1.41 (1.19–1.67) 1.62 (1.38–1.91) 1.70 (1.44–2.00) 1.81 (1.54–2.13) 0.001
Model 2 Referent 1.18 (0.99–1.41) 1.16 (0.98–1.38) 1.25 (1.05–1.48) 1.26 (1.06–1.50) 0.01
Large VLDLNMR (nmol/l) 0.1 0.2–0.5 0.6–1.8 1.9–3.8 3.8
Model 1 Referent 1.58 (1.16–2.14) 3.57 (2.71–4.70) 5.41 (4.12–7.09) 6.66 (5.10–8.70) 0.001
Model 2 Referent 1.49 (1.09–2.05) 2.54 (1.91–3.39) 2.98 (2.24–3.96) 3.11 (2.35–4.11) 0.001
Medium VLDLNMR (nmol/l) 8.2 8.3–15.9 16.0–23.8 23.9–34.1 34.1
Model 1 Referent 1.11 (0.95–1.30) 1.08 (0.92–1.27) 1.07 (0.91–1.26) 1.15 (0.98–1.35) 0.19
Model 2 Referent 1.03 (0.88–1.22) 0.99 (0.84–1.18) 0.89 (0.75–1.05) 1.04 (0.88–1.23) 0.73
Small VLDLNMR (nmol/l) 31.5 31.6–42.1 42.2–51.5 51.6–63.1 63.1
Model 1 Referent 1.50 (1.28–1.76) 1.69 (1.44–1.98) 1.79 (1.53–2.11) 1.87 (1.59–2.20) 0.001
Model 2 Referent 1.13 (0.96–1.34) 1.11 (0.94–1.31) 1.22 (1.03–1.44) 1.31 (1.10–1.55) 0.001
VLDLNMR average size (nm) 40.6 40.7–43.8 43.9–47.3 47.4–52.0 52.0
Model 1 Referent 1.23 (0.96–1.58) 1.96 (1.56–2.46) 3.31 (2.68–4.09) 4.93 (4.03–6.04) 0.001
Model 2 Referent 1.25 (0.97–1.62) 1.67 (1.32–2.10) 2.22 (1.78–2.76) 2.80 (2.27–3.46) 0.001
Data are adjusted HR (95% CI) and (ranges minimum–maximum) and are given for each quintile. See Table 2 legend for model adjustments.
S. MORA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, MAY 2010 1157positive association noted previously in relation to inci-
dent CVD in this population of women (23).
Risk factors for type 2 diabetes may differ from those for
CVD (24). For CVD risk, we reported that both small and
large LDLNMR particles had similar increase in risk, which
contrasts with the inverse association of large LDLNMR,
and positive association of small LDLNMR, with risk of
diabetes in the current study. For CVD events, NMR
lipoprotein proﬁles in this cohort of women were compa-
rable but not superior to standard lipids, as recently
reported (23). This is in contrast to the current ﬁndings for
type 2 diabetes, where NMR-measured lipoprotein classi-
ﬁcation by size provided additive and independent risk
information to standard lipids and other risk factors.
For HDL particles, the inverse association of HDLNMR
size with risk of type 2 diabetes was also noted previously
in relation to risk of CVD in this population of women (23).
Of the HDLNMR particles, only large particles were associ-
ated with lower risk of diabetes, to a magnitude similar to
the association of HDL cholesterol with diabetes, while
small particles carried higher risk. Furthermore, adjusting
for HDL cholesterol and other risk factors attenuated the
association, but larger HDLNMR size remained associated
with more than twofold increased risk. Previous studies
have found strong inverse relationships between insulin
resistance and the large HDLNMR subclass as measured by
NMR (9,10,14) or the corresponding HDL2 subclass as
measured by ultracentrifugation (25).
For VLDL particles, large particles had a greater magni-
tude of association with diabetes compared with smaller
particles, which we explain by large VLDL carrying more
triglycerides than small VLDL and correlating more with
the severity of insulin resistance (9). Hepatic overproduc-
tion of large VLDL particles is a key feature of the
dyslipoproteinemia of insulin resistance and type 2 diabe-
tes, with evidence for independent regulation of large and
small VLDL particles (26).
In addition, our ﬁnding of similar lipoprotein associa-
tions with diabetes both early and late in follow-up sug-
gests that these lipoprotein alternations may occur years
before the onset of overt hyperglycemia and clinical
diagnosis of diabetes, providing a potential opportunity for
the early detection and prevention of type 2 diabetes and
its complications.
This study has potential limitations. Several of the
risk factors were assessed by self-report. Since our
study is largely limited to Caucasian women, these data
may not be generalizable to men or other patient groups.
We studied an apparently healthy cohort at low overall























FIG. 1. Adjusted HRs and 95% CIs for quintile 5 vs. 1, unless otherwise noted, adjusted for nonlipid risk factors (age, race, randomized treatment
assignment, smoking, exercise, education, menopausal status, hormone use, blood pressure, BMI, family history of diabetes, A1C, and hsCRP).
A1C results were adjusted for age, race, randomized treatment assignment, smoking, exercise, education, menopausal status, hormone use, blood
pressure, BMI, family history of diabetes, hsCRP, and standard lipids.
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studies should be performed in the appropriate patient
settings to determine whether a strategy using NMR
lipoprotein testing is cost-effective for prevention of
type 2 diabetes and related metabolic disorders. Unde-
tected diabetes at study entry is unlikely to have biased
our results, since we excluded women with baseline
A1C levels 6.5% from our primary sample and found
similar results when we excluded those with A1C
6.0%. In addition, similar results during the ﬁrst 6
years of follow-up compared with the second 6 years.
We conclude that the size and concentration of NMR-
measured LDL, HDL, and VLDL particles were associ-
ated with clinical type 2 diabetes, independent of other
risk factors, particularly chemically measured HDL cho-
lesterol and triglycerides. The associations of LDLNMR
and HDLNMR particles with diabetes differed according
to size, with larger particles carrying lower risk and
smaller particles carrying higher risk. For VLDLNMR, large
particles were associated with higher risk. LDLNMR,
HDLNMR, and VLDLNMR particle size remained signiﬁ-
cant in models that already included standard lipids and
risk factors, adding incremental risk information be-
yond that obtained from established risk factors for type
2 diabetes.
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FIG. 2. HRs and 95% CIs were adjusted similar to Fig. 1 and stratiﬁed according to fasting (black circles) or nonfasting (gray diamonds) status.
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